The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery
The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery: a Multicentre, Parallel Group, Randomised Controlled Trial
Soren Overgaard
210 participants
Jun 9, 2025
INTERVENTIONAL
Conditions
Summary
The primary aim of this clinical trial is to investigate the effects of intravenous iron on recovery in mobility compared to the pre-fracture level in patients with a hip fracture The main questions it aims to answer are: It is hypothesize that intravenous iron will enhance gains in mobility and hereby recovery of mobility, increase hemoglobin (Hgb), lower fatigue, have a positive effect on skeletal muscles in the weeks and months after administration. The primary objective is to compare the effect of a single dose of ferric derisomaltose (FDI) (20 mg/kg body weight) relative to placebo on patients' recovery of functional mobility, measured as the change from baseline in the New Mobility Score. Participants will: \- Receive either a single dose of intravenous FDI (20 mg/kg body weight) (and saline) or placebo (saline) at 1-5 days after surgery. This trial will be conducted at three hospitals in Denmark, involving an anticipated 210 participants.
Eligibility
Inclusion Criteria6
- years of age or older
- Acute proximal femur fracture surgery
- A hemoglobin measurement ≤6.5 mmol/L (10.5 g/dL) on day 1 to 5 postoperatively
- Independent prefracture indoor walking ability, indoor NMS ≥ 2
- Ability to speak and understand Danish
- Able to provide informed consent on the participants own behalf
Exclusion Criteria11
- Known allergy to intravenous iron
- Residing permanently at a nursing home
- Hematological conditions with a risk of iron overload e.g. haemochromatosis, hemosiderosis, or where alternative treatments are necessary e.g. haematological malignancies
- Other contraindication to iron treatment, e.g. severe liver cirrhosis and hepatitis
- Severe uncontrolled infection as assessed by the responsible clinician (e.g. bacteraemia or sepsis)
- Plasma sodium levels below 125 or above 150 mmol/L on the day of inclusion
- Renal replacement therapy
- Severe dementia assessed by physician
- Recent intravenous iron injection, 4 weeks prior to surgery
- Patient declared terminally ill
- Pathologic Fracture
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The active intervention is a single dose of Ferric Derisomaltose, 20mg/kg body weight, diluted in 100 mL isotonic sodium chloride 0.9%
Single dose of 100 mL isotonic sodium chloride 0.9%
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06898814